[go: up one dir, main page]

MX2012003951A - Preparacion farmceutica que comprende hcg recombinante. - Google Patents

Preparacion farmceutica que comprende hcg recombinante.

Info

Publication number
MX2012003951A
MX2012003951A MX2012003951A MX2012003951A MX2012003951A MX 2012003951 A MX2012003951 A MX 2012003951A MX 2012003951 A MX2012003951 A MX 2012003951A MX 2012003951 A MX2012003951 A MX 2012003951A MX 2012003951 A MX2012003951 A MX 2012003951A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
recombinant hcg
hcg
recombinant
including recombinant
Prior art date
Application number
MX2012003951A
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2012003951A publication Critical patent/MX2012003951A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a preparaciones que incluyen la hCG recombinante (rhCG).
MX2012003951A 2009-10-05 2010-10-04 Preparacion farmceutica que comprende hcg recombinante. MX2012003951A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05
PCT/GB2010/001854 WO2011042688A1 (en) 2009-10-05 2010-10-04 Pharmaceutical preparation comprising recombinant hcg

Publications (1)

Publication Number Publication Date
MX2012003951A true MX2012003951A (es) 2012-05-29

Family

ID=41471027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003951A MX2012003951A (es) 2009-10-05 2010-10-04 Preparacion farmceutica que comprende hcg recombinante.

Country Status (25)

Country Link
US (5) US8975226B2 (es)
EP (2) EP2486051B1 (es)
JP (6) JP6176924B2 (es)
KR (7) KR20210014767A (es)
CN (1) CN107050434B (es)
AR (2) AR079876A1 (es)
AU (1) AU2010304922B2 (es)
BR (1) BR112012007990A2 (es)
CA (1) CA2776790A1 (es)
DK (1) DK2486051T3 (es)
ES (2) ES2798258T3 (es)
HR (1) HRP20200941T1 (es)
HU (1) HUE050793T2 (es)
IL (3) IL218548A (es)
IN (1) IN2012DN02073A (es)
JO (1) JOP20200039A1 (es)
LT (1) LT2486051T (es)
MX (1) MX2012003951A (es)
PL (1) PL2486051T3 (es)
PT (1) PT2486051T (es)
RS (1) RS60413B1 (es)
RU (2) RU2724528C2 (es)
SI (1) SI2486051T1 (es)
TW (2) TWI532495B (es)
WO (1) WO2011042688A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2691119B1 (en) * 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
WO2012168680A1 (en) * 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2930241B1 (en) 2012-12-10 2019-06-26 Seikagaku Corporation Novel recombinant factor c and method for producing same, and method for measuring endotoxin
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
MX389908B (es) 2015-04-24 2025-03-20 Ferring Bv Metodo de produccion de gonadotrofina.
MX381279B (es) 2015-06-26 2025-03-12 Ferring Bv Métodos de purificación y/o inactivación viral.
EP4534145A3 (en) 2018-04-30 2025-07-02 Ferring B.V. Composition for controlled ovarian stimulation
WO2021156720A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressing il-15 heterodimers
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
PT814841E (pt) * 1995-03-21 2002-03-28 Applied Research Systems Formulacoes liquidas de hcg
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
KR100706469B1 (ko) 1997-06-25 2007-04-10 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 이황화결합으로 연결된 당단백질 호르몬 유사체, 이의제조방법 및 이의 용도
US6500627B1 (en) * 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
US7304031B2 (en) * 2001-10-29 2007-12-04 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
WO2003050286A1 (en) * 2001-10-29 2003-06-19 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
WO2000067778A1 (en) 1999-05-07 2000-11-16 Applied Research Systems Ars Holding N.V. Gonadotrophins
EP1257564B1 (en) * 2000-02-22 2008-08-27 Laboratoires Serono SA Process for purification of recombinant hcg having a specific bioactivity
EP1425032A2 (en) 2001-09-12 2004-06-09 Applied Research Systems ARS Holding N.V. USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
ATE329930T1 (de) 2001-10-22 2006-07-15 Applied Research Systems Fsh-zusammensetzungen mit hohem sialylierungsgrad und deren verwendung zur herstellung von arzneimitteln
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
EP2338333B1 (en) * 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
PL1654353T3 (pl) * 2003-08-18 2013-11-29 Glycotope Gmbh Nowotworowe linie komórkowe NM-F9 (DSM ACC2606) i NM-D4 (DSM ACC2605) oraz ich zastosowanie
WO2005076013A2 (en) * 2004-02-04 2005-08-18 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
CN1926242B (zh) * 2004-02-13 2013-01-16 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
CN101137396A (zh) * 2005-03-11 2008-03-05 弗雷泽纽斯卡比德国有限公司 由无活性初始材料制备生物活性糖蛋白
DE112006002122B4 (de) * 2005-08-15 2016-09-22 Continental Automotive Systems, Inc. ( n. d. Ges. d. Staates Delaware ) Dieselabgas-Kohlenwasserstoff-Dosierventil für Fahrzeuge
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 dna칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
US20080280818A1 (en) * 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) * 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2691119B1 (en) * 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
JP6580104B2 (ja) 2019-09-25
US9676835B2 (en) 2017-06-13
RS60413B1 (sr) 2020-07-31
CA2776790A1 (en) 2011-04-14
JP2021176867A (ja) 2021-11-11
JP7292153B2 (ja) 2023-06-16
US11292824B2 (en) 2022-04-05
JP6310440B2 (ja) 2018-04-11
IL218548A0 (en) 2012-05-31
CN102549011A (zh) 2012-07-04
HUE050793T2 (hu) 2021-01-28
AR125991A2 (es) 2023-08-30
EP3611185A1 (en) 2020-02-19
AU2010304922B2 (en) 2014-11-06
IL267556A (en) 2019-08-29
JP2018076296A (ja) 2018-05-17
JP2023075144A (ja) 2023-05-30
SI2486051T1 (sl) 2020-08-31
US20220340634A1 (en) 2022-10-27
ES3036152T3 (en) 2025-09-15
JP6176924B2 (ja) 2017-08-09
JP2016074680A (ja) 2016-05-12
US12234272B2 (en) 2025-02-25
PL2486051T3 (pl) 2020-09-07
TW201632198A (zh) 2016-09-16
TWI532495B (zh) 2016-05-11
HRP20200941T1 (hr) 2020-09-18
RU2016118236A3 (es) 2019-09-18
KR102489143B1 (ko) 2023-01-13
JOP20200039A1 (ar) 2022-10-30
WO2011042688A1 (en) 2011-04-14
IN2012DN02073A (es) 2015-08-21
EP3611185B1 (en) 2025-04-30
AR079876A1 (es) 2012-02-29
TW201113030A (en) 2011-04-16
KR20210014767A (ko) 2021-02-09
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
PT2486051T (pt) 2020-06-17
LT2486051T (lt) 2020-07-10
IL250733A0 (en) 2017-04-30
DK2486051T3 (da) 2020-06-22
KR101804479B1 (ko) 2017-12-05
EP2486051B1 (en) 2020-03-25
JP2013506708A (ja) 2013-02-28
RU2724528C2 (ru) 2020-06-23
CN107050434B (zh) 2021-07-27
KR20170133531A (ko) 2017-12-05
AU2010304922A1 (en) 2012-03-29
US20130023476A1 (en) 2013-01-24
US20180030107A1 (en) 2018-02-01
IL218548A (en) 2017-03-30
RU2016118236A (ru) 2018-10-29
KR20210141771A (ko) 2021-11-23
ES2798258T3 (es) 2020-12-10
US20140249082A1 (en) 2014-09-04
US20200247863A1 (en) 2020-08-06
RU2588650C2 (ru) 2016-07-10
KR102213154B1 (ko) 2021-02-05
RU2012112907A (ru) 2013-11-10
KR20230012104A (ko) 2023-01-25
KR101987982B1 (ko) 2019-06-11
EP2486051A1 (en) 2012-08-15
US10526390B2 (en) 2020-01-07
US8975226B2 (en) 2015-03-10
JP2020000246A (ja) 2020-01-09
KR20190028823A (ko) 2019-03-19
IL250733B (en) 2019-07-31
CN107050434A (zh) 2017-08-18
BR112012007990A2 (pt) 2017-07-25
JP7196244B2 (ja) 2022-12-26
KR20190067256A (ko) 2019-06-14

Similar Documents

Publication Publication Date Title
MX2012003951A (es) Preparacion farmceutica que comprende hcg recombinante.
EP4302783A3 (en) Modified relaxin polypeptides and their uses
MY197851A (en) Antibody formulations
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
PH12013502671A1 (en) Glucagon/glp-1 receptor co-agonists
ZA201208541B (en) Antibody preparations
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
ZA201406382B (en) Levoisovalerylspiramycin i,ii,iii and preparations ,preparation methods and uses thereof
IN2012DN03404A (es)
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
EP3157554A4 (en) Compositions, methods and therapies for administering antigen peptide
IN2013MN00733A (es)
MX2015012905A (es) Formulaciones de factor viii recombinantes.
WO2012131306A8 (en) Pharmaceutical preparation
MX2012012489A (es) Preparacion de polipeptidos y sales de los mismos.
JO3497B1 (ar) مستحضر صيدلي يشتمل على hcg مأشوب
MX366768B (es) Tableta orodispersable de sildenafil y metodo para preparar la misma.
JO3808B1 (ar) Fsh ناتج عن عودة الاتحاد الجيني يشتمل على إضافة مجموعة سياليل عند ألفا 2, 3- وألفا
HK1167663A (en) Ttk peptides and vaccines including the same
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
AU2010904032A0 (en) Modified relaxin polypeptides
UA54718U (ru) Конструкция для выравнивания пола
HK1180595A (zh) 浓缩蛋白制剂及其用途
TN2013000524A1 (en) Glucagon/glp-1 receptor co-agonists

Legal Events

Date Code Title Description
FG Grant or registration